Andera Partners, formerly Edmond de Rothschild Investment Partners, is a venture capital firm. They invest across four strategies, BioDiscovery, Cabestan Capital, Winch Capital and ActoMezz. Across their four strategies, they have €2.3 billion under management with 95 portfolio companies.
Andera Partners' BioDiscovery invests in companies working in medical therapy, products and technologies from pre-clinical to proof of principles to commercialization.
Andera Partners' Cabestan Capital makes equity investments in French companies to develop them into cross border companies.
Andera Partners' Winch Capital invests in European companies with a revenue of €30 millioin to €300 million, in which they invest between €12 million to €45 million.
Andera Partners' ActoMezz invests between €5 to €45 million in small to mid-cap French companies who are either sponsorless, need capital for growth or looking to maximize the participation of directors in transfer transactions.
Andera Partners has made investments in Inotrem, AM Pharma, SANIFIT, HR Path, Arvelle Therapeutics, Grey Wolf Therapeutics, HighLife, Atlantic Therapeutics, Artios Pharma and ReViral.
They have exited their investments in Axonics Modulation Technologies, Vivoryon Therapeutics, LogicBio Therapeutics, Poxel, SuperSonic Imagine, EOS Imaging, Exclusive Group, CellNovo, Verona Pharma and Noxxon Pharma.
